bpc 157 human clinical trials gastrointestinal Peptide BPC-157 BPC-157 – No Proof Required!

BPC-157 has shown promising results in preclinical research for treating various conditions, including muscle and tendon injuries, gastrointestinal disorders, and inflammation

Ingram MA, Jones MB, Stonehouse W, et al

2022 Jul 24:S0002-9629(22)00313-5

BPC-157 Therapy The BPC-157 peptide is characterized by its ability to inhibit the increased expression of -defensins, LL-37, RNase 7, psoriasin, and lysozyme, which may make it one of the main factors responsible for reduced susceptibility to skin infections in patients with psoriasis

The route and format are determined at the APRN intake based on the primary indication, which is why individualized assessment before prescribing is essential rather than optional